To find consensus in a difficult task between the patient, disease, doctor, and insurance company. What stands in the way of successful treatment of patients with dry eye by using such high technologies as BlephEx and LipiFlow? Review of the paradox in the pathophysiology of the dry eye mechanism and all known methods of treating.
Whose financial obligation it would be to pay for the special medication that could cure the rarest diseases? While we are discussing this topic, hope that professors of ethics, philosophers, and economists would consider this issue.
